199 related articles for article (PubMed ID: 24726555)
1. Pathogen safety of Beriate®.
Gröner A
Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
[TBL] [Abstract][Full Text] [Related]
2. Pathogen safety of plasma-derived products - Haemate P/Humate-P.
Gröner A
Haemophilia; 2008 Nov; 14 Suppl 5(Suppl 5):54-71. PubMed ID: 18786011
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate® P) in patients with haemophilia A.
Klamroth R; Gottstein S; Orlovic M; Heinrichs C
Thromb Res; 2014 Nov; 134 Suppl 1():S38-42. PubMed ID: 24256767
[TBL] [Abstract][Full Text] [Related]
4. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
5. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
6. Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.
Klamroth R; Holzhauer S; Zimmermann R; Heller C; Kurnik K;
Thromb Res; 2014 Nov; 134 Suppl 1():S16-21. PubMed ID: 24418255
[TBL] [Abstract][Full Text] [Related]
7. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of continuous infusion with Beriate® P in patients with severe haemophilia A undergoing surgery - a subgroup analysis.
Auerswald G; Bade A; Johne J; Haubold K; Overberg D; Masurat S; Moorthi C
Thromb Res; 2014 Nov; 134 Suppl 1():S43-7. PubMed ID: 24360932
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
10. Twenty years of treatment with Beriate® P.
Brackmann HH
Thromb Res; 2014 Nov; 134 Suppl 1():S1-3. PubMed ID: 24360930
[No Abstract] [Full Text] [Related]
11. Assessment of needs for plasma for fractionation in Europe.
Burckhardt JJ
Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
[TBL] [Abstract][Full Text] [Related]
12. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
13. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
Klamroth R; Gröner A; Simon TL
Transfusion; 2014 May; 54(5):1406-17. PubMed ID: 24117799
[TBL] [Abstract][Full Text] [Related]
14. Treatment of haemophilia patients in East Germany prior to and after reunification in 1990.
Lenk H
Thromb Res; 2014 Nov; 134 Suppl 1():S57-60. PubMed ID: 24745720
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes.
Farcet MR; Lackner C; Antoine G; Rabel PO; Wieser A; Flicker A; Unger U; Modrof J; Kreil TR
Transfusion; 2016 Feb; 56(2):383-91. PubMed ID: 26399175
[TBL] [Abstract][Full Text] [Related]
16. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
17. Challenges for new haemophilia products from a manufacturer's perspective.
Schulte S
Thromb Res; 2014 Nov; 134 Suppl 1():S72-6. PubMed ID: 24360931
[TBL] [Abstract][Full Text] [Related]
18. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
19. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia.
Mariani G; Di Paolantonio T; Baklaya R; Morfini M; Mannucci PM
Transfusion; 1993 Oct; 33(10):814-8. PubMed ID: 8236421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
